https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-00041
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
phesgomaintenancedxdshortinduction
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid?sf166541819=1
FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation
accelerated approvalin combinationfdagrantsdabrafenib
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancer?utm_medium=email&utm_source=govdelivery
On April 8, 2025, the FDA approved nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab (Yervoy, Bristol Myers Squibb Company) for adult and...
fdanivolumabipilimumabunresectablemetastatic
https://www.healthday.com/healthpro-news/cancer/high-response-to-pd-1-therapy-seen-in-unresectable-desmoplastic-melanoma
Patients with advanced desmoplastic melanoma have high response to single-agent anti-programmed death protein 1 therapy.
desmoplastic melanomahighresponsepdtherapy
https://pubmed.ncbi.nlm.nih.gov/21448934/
Proton therapy to deliver high radiotherapy doses allows locally curative treatment for some patients with unresectable or incompletely resected OSA.
protonbasedradiotherapyunresectableresected
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancer
On April 8, 2025, the FDA approved nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab (Yervoy, Bristol Myers Squibb Company) for adult and...
fdanivolumabipilimumabunresectablemetastatic